Skip to main content

Table 2 Baseline characteristics of treated migraine attacks for patients using and not using migraine preventive medications

From: Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials

Characteristic (ITT population)

Using preventive treatments N = 698

Not using preventive treatments N = 3283

Baseline migraine severity

 Severe, n (%)

174 (24.9)

973 (29.6)

 Moderate, n (%)

511 (73.2)

2257 (68.7)

 Mild, n (%)

13 (1.9)

52 (1.6)

Time to dosing from onset of pain in hours, mean (SD)

1.9 (4.3)

1.9 (4.3)

Baseline symptoms

 Photophobia, n (%)

537 (76.9)

2522 (76.8)

 Phonophobia, n (%)

439 (62.9)

2048 (62.4)

 Nausea, n (%)

316 (45.3)

1416 (43.1)

 Vomiting, n (%)

14 (2.0)

80 (2.4%)

Baseline disability score

 Need complete bedrest, n (%)

118 (16.9)

585 (17.8)

 Marked interference, n (%)

363 (52.0)

1795 (54.7)

 Mild interference, n (%)

209 (29.9)

862 (26.3)

 Not at all, n (%)

8 (1.1)

41 (1.2)

  1. ITT intent-to-treat, N number of patients in subgroup of ITT population, n number of patients with stated characteristic, SD standard deviation
  2. p < 0.05 compared with not using preventives